Tech Company Financing Transactions
Inimmune Funding Round
Inimmune, operating out of Missoula, secured $22 million in investment from Two Bear Capital and private investors.
Transaction Overview
Company Name
Announced On
7/13/2020
Transaction Type
Venture Equity
Amount
$22,000,000
Round
Series A
Investors
Two Bear Capital (Lead Investor) (Michael Goguen)
Proceeds Purpose
The company plans to use the Series A investment to advance at least two late-stage pre-clinical drug candidates in oncology and allergy through Phase I human clinical trials.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1121 East Bdwy. 121
Missoula, MT 59802
USA
Missoula, MT 59802
USA
Phone
Undisclosed
Website
Email Address
Overview
Inimmune is a promising new biotechnology company founded by pharmaceutical industry veterans, focused on developing the next generation of next generation vaccines and immunotherapeutics. The group has extensive expertise in synthetic and process chemistry, drug formulation, and immunology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jay Evans
Chief Operating Officer
David Burkhart
Vice President
Helene Bazin-Lee
VP - General Counsel
Michael Conger
VP - Manufacturing
Kendal Ryter
Browse more venture capital transactions:
Prev: 7/13/2020: Joe Coffee venture capital transaction
Next: 7/13/2020: Perfect Day venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs